Close Menu

NEW YORK – Abbott said after the close of the market on Friday that the US Food and Drug Administration issued Emergency Use Authorization for the company's point-of-care test for detection of SARS-CoV-2.

According to the Abbott Park, Illinois-based firm, the test, which will run on its ID Now platform, can provide positive results in as little as five minutes and negative results in 13 minutes, and it can be used in a variety of healthcare settings, including doctors' offices, urgent care clinics, and hospital emergency departments.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

An Associated Press report says China refrained from releasing the SARS-CoV-2 genome for more than a week in January, frustrating the World Health Organization.

The Lancet and the New England Journal of Medicine have issued expressions of concern regarding the data used in two COVID-19 papers, the New York Times reports. 

Researchers have sequenced the genome of the mayfly, garnering insight into how insects evolved wings, Science reports.

In Genome Research this week: gene expression in primate brain regions, inversions and breakpoint inverted repeats in the human genome, and more.